相似文献
1
alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding.
Thorax. 2004 Aug;59(8):708-12. doi: 10.1136/thx.2003.006544.
2
Key current clinical issues in alpha-1 antitrypsin deficiency.
Respir Care. 2003 Dec;48(12):1216-21; discussion 1221-4.
3
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27.
4
[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].
Pneumologie. 1998 Oct;52(10):545-52.
5
High dose intravenous AAT and plasma neutrophil derived fibrinogen fragments.
Thorax. 2005 Jan;60(1):84; author reply 84.
6
[Substitution therapy in alpha 1-antitrypsin deficiency].
Pneumologie. 2001 Jan;55(1):1-3. doi: 10.1055/s-2001-10444.
7
Alpha 1-antitrypsin deficiency and the impact of nursing interventions and treatment with intravenous therapy. An overview.
J Intraven Nurs. 1999 Sep-Oct;22(5):258-64.
8
A review of augmentation therapy for alpha-1 antitrypsin deficiency.
Expert Opin Biol Ther. 2012 Jun;12(6):685-700. doi: 10.1517/14712598.2012.676638. Epub 2012 Apr 14.
9
Alpha1-antitrypsin augmentation therapy.
Chest. 1997 Oct;112(4):872-4. doi: 10.1378/chest.112.4.872.
10
Alpha-1-antitrypsin replacement therapy: current status.
Curr Opin Pulm Med. 2006 Mar;12(2):125-31. doi: 10.1097/01.mcp.0000208452.57854.c6.
引用本文的文献
1
Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency.
J Bras Pneumol. 2024 Dec 6;50(5):e20240235. doi: 10.36416/1806-3756/e20240235. eCollection 2024.
2
How are we in Brazil with the treatment of alpha-1 antitrypsin deficiency?
J Bras Pneumol. 2022 Apr 29;48(3):e20210045. doi: 10.36416/1806-3756/e20210045.
3
There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements.
Int J Chron Obstruct Pulmon Dis. 2021 Mar 29;16:835-840. doi: 10.2147/COPD.S298585. eCollection 2021.
4
Alpha-1-antitrypsin: A possible host protective factor against Covid-19.
Rev Med Virol. 2021 Mar;31(2):e2157. doi: 10.1002/rmv.2157. Epub 2020 Aug 26.
5
Advances in managing COPD related to α -antitrypsin deficiency: An under-recognized genetic disorder.
Allergy. 2018 Nov;73(11):2110-2121. doi: 10.1111/all.13558. Epub 2018 Jul 26.
6
Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy.
Eur Respir Rev. 2015 Mar;24(135):46-51. doi: 10.1183/09059180.10010714.
7
Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells.
Front Public Health. 2013 Jun 21;1:19. doi: 10.3389/fpubh.2013.00019. eCollection 2013.
8
Adipose tissue-derived mesenchymal stem cell-based liver gene delivery.
J Hepatol. 2011 May;54(5):930-8. doi: 10.1016/j.jhep.2010.07.051. Epub 2010 Nov 3.
9
Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin.
Mol Ther. 2010 Aug;18(8):1553-8. doi: 10.1038/mt.2010.116. Epub 2010 Jun 15.
10
New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.
Dermatology. 2009;218(4):370-5. doi: 10.1159/000202982. Epub 2009 Feb 16.
本文引用的文献
1
Major components of the direct medical costs of alpha1-antitrypsin deficiency.
Chest. 2003 Sep;124(3):826-31. doi: 10.1378/chest.124.3.826.
2
Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
Chest. 2003 May;123(5):1425-34. doi: 10.1378/chest.123.5.1425.
3
Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency.
Am J Respir Crit Care Med. 2003 May 15;167(10):1387-92. doi: 10.1164/rccm.200209-1035OC. Epub 2003 Feb 5.
4
Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.
Chest. 2002 Jul;122(1):66-74. doi: 10.1378/chest.122.1.66.
5
The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
Am J Respir Crit Care Med. 2002 Jun 1;165(11):1494-8. doi: 10.1164/rccm.2109013.
6
The direct medical costs of alpha(1)-antitrypsin deficiency.
Chest. 2001 Mar;119(3):745-52. doi: 10.1378/chest.119.3.745.
7
Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.
Chest. 2001 Mar;119(3):737-44. doi: 10.1378/chest.119.3.737.
8
Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.
Am J Respir Crit Care Med. 2000 Dec;162(6):2069-72. doi: 10.1164/ajrccm.162.6.2002032.
9
Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
Chest. 2000 Nov;118(5):1480-5. doi: 10.1378/chest.118.5.1480.
10
Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis.
Chest. 2000 Mar;117(3):875-80. doi: 10.1378/chest.117.3.875.
Zotero 插件